Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia

Retina

Volumn 29, Issue 6, 2009, Pages 750-756

  Lai, Timothy Y Y ^a   Chan, Wai Man ^a,b,c   Liu, David T L ^b   Lam, Dennis S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DRUG EFFICACY; ENDOPHTHALMITIS; EYE INFECTION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOVEOSCHISIS; HUMAN; INTRAOCULAR PRESSURE; MALE; MEDICAL RECORD REVIEW; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; REFRACTION ERROR; RETINA DETACHMENT; RETINA DISEASE; RETINA FOVEA; RETINA TEAR; RETROSPECTIVE STUDY; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 67749091135     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31819ed6bd     Document Type: Article

References (24)

1. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
2. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol 2003;87:570-573.
3. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. Ophthalmology 2002;109: 712-719.
4. Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 2005;89:1522- 1528.
5. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001;108:841-852.
6. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003;110:667-673.
7. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003;87:173-176.
8. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathologic myopia: a pilot study. Br J Ophthalmol 2007;91: 174-179.
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
10. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
11. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372.
12. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
13. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26: 495-511.
14. Bhatnagar P, Spaide RF, Takahashi BS, et al. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007;27:846-850.
15. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevaci-zumab (avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444.
16. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 2007;91:157-160.
17. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 2007;91:161-165.
18. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for sub-foveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-712.
19. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevaci-zumab (avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-2196.
20. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150 -154.
21. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-1123.
22. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008 [Epub ahead of print].
23. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143:566-583.
24. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.